Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Founded in 2007 and headquartered in Waltham, Massachusetts, the company has built its pipeline by identifying, acquiring, and in-licensing proprietary development-stage compounds with innovative mechanisms of action. Its lead product candidate, roluperidone, is being developed as a potential first-in-class treatment for negative symptoms in patients with schizophrenia. The company's strategy centers on leveraging randomized clinical trial data to advance candidates across multiple regulatory jurisdictions while selectively exploring collaborations with major pharmaceutical partners to maximize program value.